Potential therapeutic target cells of multiple sclerosis-myeloid cells
10.16438/j.0513-4870.2018-0189
- VernacularTitle:多发性硬化症的潜在治疗靶细胞——髓系细胞
- Author:
Hong-mei NIU
1
;
Ming-yang WANG
1
;
Lin LI
1
Author Information
1. Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Engineering Research Center for Nerve System Drugs, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China
- Publication Type:SPECIAL REPORTS
- Keywords:
multiple sclerosis;
myeloid cell;
dendritic cell;
monocyte;
macrophage;
microglia;
proinflammatory factor
- From:
Acta Pharmaceutica Sinica
2018;53(7):1030-1035
- CountryChina
- Language:Chinese
-
Abstract:
The discussion on pathophysiological of multiple sclerosis (MS) mainly focuses on T and B cells in adaptive immune response, but less involve in the myeloid cells (dendritic cells, monocytes, macrophages and microglia) in the innate immune system, which also play an important role in the pathogenesis of MS. The myeloid cell population acts as antigen-presenting cells and effector cells in neuroinflammation in the innate immune system. The interactions between T cells and myeloid cells form a vicious cycle which makes the disease continuous deterioration. At present, the studies on the therapeutic drugs for MS mainly are focused on the adaptive immune system, but pay less attention to myeloid cells. In this article, we reviewed the sub-types and functions of myeloid cells, their changes in MS patients and animal models, as well as the effects of some therapeutic drugs for MS on myeloid cells, in the purpose of finding new targets and strategies for development for MS therapy.
